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Aims We aimed to determine the relation between baseline systolic blood pressure (SBP), change in SBP, and worsening
renal function (WRF) in acute heart failure (AHF) patients enrolled in the Pre-RELAX-AHF trial.
Methods
and results
The Pre-RELAX-AHF study enrolled 234 patients within 16 h of admission (median 7 h) for AHF and randomized
them to relaxin given intravenous (i.v.) for 48 h or placebo. Blood pressure was measured at baseline, at 3, 6, 9,
12, 24, 36, and 48 h and at 3, 4, and 5 days after enrolment. Worsening renal function was defined as a serum crea-
tinine increase of ≥0.3 mg/dL by Day 5. Worsening renal function was found in 68 of the 225 evaluable patients
(30%). Patients with WRF were older (73.5+9.4 vs. 69.1+10.6 years; P ¼ 0.003), had a higher baseline SBP
(147.3+19.9 vs. 140.8+16.7 mmHg; P ¼ 0.01), and had a greater early drop in SBP (37.9+16.0 vs.
31.4+ 12.2 mmHg; P ¼ 0.004). In a multivariable model, higher age, higher baseline creatinine, and a greater early
drop in SBP, but not baseline SBP, remained independent predictors of WRF. Furthermore, WRF was associated
with a higher Day 60 (P ¼ 0.01), and Day 180 (P ¼ 0.003) mortality.
Conclusions Worsening renal function in hospitalized AHF patients is related to a poor clinical outcome and is predicted by a
greater early drop in SBP.
Trial registration clinicaltrials.gov identifier NCT00520806.
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Introduction
Renal dysfunction is a frequent finding in patients hospitalized for
acute heart failure (AHF) and it is related to a poorer prognosis.1
In addition, further deterioration of renal function [worsening renal
function (WRF)] occurs in approximately one-third of patients.2–7
Worsening renal function during hospitalization was found to be
strongly related to a poorer outcome as well, independent of base-
line renal function.2–9 Moreover, the occurrence of WRF during
HF-related hospitalization is associated with higher hospitalization
costs and longer hospital stay.8 Early identification of patients at
risk of WRF is therefore clinically important.
Several studies have identified factors associated with WRF.
Two of the most common predictors of WRF are a poorer
renal function at admission and the presence of diabetes.3–10 In
some studies, higher blood pressure at admission was also
related to a greater risk of WRF.3–5,11,12 This is consistent with
the finding that patients with hypertension are more likely to
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have an increase in serum creatinine concentration when the blood
pressure is lowered.13 However, none of these studies reported
on the change in blood pressure related to WRF, in particular in
patients with hypertension.
The relaxin for the treatment of patients with acute heart failure
trial (Pre-RELAX-AHF) was a multicentre pilot phase trial aimed at
the assessment of the dose response and effects on symptoms,
outcomes, and safety of relaxin, a natural human peptide with vaso-
dilator properties, in patients with AHF and preserved or elevated
systolic blood pressure. The study demonstrated a favourable
effect of relaxin on dyspnoea improvement and clinical outcomes,
which was also associated with a reduced use of diuretics.14,15 In
the Pre-RELAX-AHF trial, blood pressure and serum creatinine
were measured serially during the first 5 days of hospitalization.
In the current study, we evaluated the relation between baseline
blood pressure, an early change in blood pressure, and the risk
of WRF in patients hospitalized for AHF and included in the
Pre-RELAX-AHF study.
Methods
Patients
The present study included patients enrolled in the Pre-RELAX-AHF
study.14 (Appendix) The design and results of Pre-RELAX-AHF have
been described extensively elsewhere.14 In brief, men and women
aged .18 years, hospitalized for AHF, with a systolic blood pressure
(SBP) . 125 mmHg, and with impaired renal function (estimated glo-
merular filtration rate of 30–75 mL/min/1.73 m2, calculated with the
simplified modification of diet in renal disease [sMDRD] equation),16
were eligible for inclusion in the study. Acute heart failure was
defined by the presence of all of the following at screening: dyspnoea
at rest or with minimal exertion, pulmonary congestion on chest X-ray,
and elevated natriuretic peptide levels [brain natriuretic peptide (BNP)
≥ 350 ng/L or NT-proBNP ≥ 1400 ng/L].
Procedures
The study was approved by the relevant ethics committees, insti-
tutional review boards, and regulatory authorities, and conducted
under the International Conference on Harmonization Good Clinical
Practice guidelines. All patients provided informed written consent
prior to participation. By protocol, the study drug infusion was to be
terminated if the patient’s SBP was reduced to ,100 mmHg or by
.40 mmHg compared with baseline, in two successive measurements
taken 15 min apart. Investigators were not prohibited from utilizing any
standard medication thought necessary to treat patients enrolled in the
study, including additional vasodilators.
Blood pressure was measured at baseline, at 3, 6, 9, 12, 24, 36, and
48 h and at Days 3, 4, and 5. Blood samples for laboratory measure-
ments, including serum creatinine, were taken at baseline and at
12 h, then daily through to discharge, at Days 5 and 14, and were ana-
lysed at a central laboratory. Vital status and rehospitalization infor-
mation was collected over the telephone on Days 30, 60, and (vital
status only at) 180. When the last enrolled patient reached Day 60,
all patients who were between Day 60 and Day 180 of follow-up
were contacted by telephone, to complete the study.
Definitions
Baseline SBP was the average of the screening and baseline measure-
ment. All blood pressure measurements were performed supine,
after 5 min of rest.
Peak drop in SBP was calculated as the difference between baseline
and the lowest value measured during the first 48 h of the study.
Worsening renal function was defined as an increase in serum
creatinine of 0.3 mg/dL or more from baseline at any time
through Day 5. Subjects who died prior to Day 5 were omitted
from the analysis.
Statistical analysis
For continuous variables, means+ standard deviations are shown,
unless otherwise noted, and means are compared using t-tests. Pro-
portions were compared using x2 tests. The ordered categorical
variable New York Heart Association (NYHA) class was compared
using a Cochran–Mantel–Haenszel test. Odds ratios (OR) and
associated confidence intervals (CI), and P-values for Wald x2
tests, for predictors of WRF were computed from logistic
regression models, and are presented for a 1SD increase (or
decrease) for continuous variables. Multivariable-adjusted predictors
of WRF were assessed in a logistic regression model. Candidate
variables entered into this model included predictors of WRF
during hospitalization for AHF previously identified by others and
found to be associated with WRF with P , 0.20 in the present
study, i.e. age, baseline SBP, NYHA-class, BNP, and baseline
serum creatinine.3–11,15–17 Additional models were made for
adjustment for all previous factors with weight change, relaxin treat-
ment, and dose of diuretics added. A backward selection procedure
was used with the criterion for keeping at a ¼ 0.1. Kaplan–Meier
estimates of the rates of all-cause mortality through Days 60 and
180, cardiovascular death through Day 180, and heart failure
re-admission through Day 60 are presented. Event times of
5 days or less were excluded from these analyses. Patients with
and without WRF were compared using log-rank tests. Length of
initial hospital stay was set to the maximum observed value +1
for subjects who died in-hospital. Groups were compared with
respect to days alive out of hospital and length of initial hospital
stay using Wilcoxon rank sum tests.
Results
Patients
The patients’ characteristics have been extensively described
elsewhere.14,15 In brief, 234 AHF patients were entered into
the study. Creatinine values that allowed a classification of
WRF were available for 225 (96%) of these patients; two patients
who died within 5 days and two patients with no follow-up crea-
tinine value (and thus a determination of WRF could not be
made) were excluded from the analysis. Mean age of the
present patient population was 70.4+10.4 years, 55.6% were
male, 96.9% were white, 85.8% had a history of hypertension,
and 69.6% had ischaemic heart failure.
Prevalence and clinical correlates
of worsening renal function
Worsening renal function was found in 68 of the 225 evaluable
patients (30%). Characteristics of patients with and without
A.A. Voors et al.962
 at European Society of Cardiology on M
ay 20, 2012
http://eurjhf.oxfordjournals.org/
D
ow
nloaded from
 
WRF are shown in Table 1. Patients with WRF were older
(73.5+9.4 vs. 69.1+10.6 years; P ¼ 0.003), had a higher base-
line SBP (147.3+ 19.9 vs. 140.8+16.7; P ¼ 0.01), and had a
greater early drop in SBP (37.9+16.0 vs. 31.4+12.2;
P ¼ 0.004) through the first 48 h. Figure 1 shows that the drop
in SBP during the first 5 days was larger in patients developing
WRF. This difference was particularly evident during the first
few hours.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 1 Baseline characteristics of patients with and without worsening renal function
Worsening renal function P-value
Yes (n 5 68) No (n 5 157)
Mean (SD) or (%) Mean (SD) or (%)
Age (years) 73.5 (9.4) 69.1 (10.6) 0.003
Male 54.4% 56.1% 0.82
Medical history
Atrial fibrillation 39.7% 51.9% 0.09
Asthma, bronchitis, or COPD 17.6% 15.9% 0.75
Diabetes 47.0% 42.3% 0.52
Hypertension 89.7% 84.1% 0.27
Ischaemic heart failure 73.5% 67.9% 0.40
Peripheral vascular disease 19.1% 10.2% 0.07
Stroke 17.6% 15.9% 0.75
NYHA class 1 month prior to presentation
1 0 4 (2.8%) 0.33
2 18 (30.5%) 32 (22.7%)
3 18 (30.5%) 70 (49.7%)
4 23 (39.0%) 35 (24.8%)
Baseline vital signs
Systolic blood pressure (mmHg) 147.3 (19.9) 140.8 (16.7) 0.01
Diastolic blood pressure (mmHg) 81.9 (14.4) 80.3 (12.3) 0.38
Pulse (bpm) 81.1 (14.5) 81.1 (14.9) 0.98
Weight (kg) 79.4 (15.5) 81.8 (18.2) 0.36
Baseline laboratory values
BNP.500 or NT-proBNP.2000 pg/mL 80.9% 71.3% 0.13
Haemoglobin (g/dL) 13.0 (1.7) 13.1 (1.8) 0.66
BUN (mg/dL) 28.8 (12.4) 26.4 (11.1) 0.14
Serum creatinine (g/dL) 1.4 (0.5) 1.3 (0.4) 0.19
eGFR (sMDRD) 55.9 (22.2) 59.4 (19.8) 0.24
Changes during treatment
Lowest SBP within 48 h (mmHg) 112.6 (16.7) 111.6 (13.5) 0.66
Peak drop in SBP within 48 h (mmHg) 37.9 (16.0) 31.4 (12.2) 0.004
Total dose intravenous loop diuretics
Day 0 39.4 (75.1) 22.8 (43.8) 0.0386
Day 1 90.3 (164.5) 31.0 (38.6) ,0.0001
Days 0 and 1 129.7 (210.1) 53.7 (65.6) ,0.0001
Medications administered from presentation to randomization
ACE inhibitor 40 (58.8%) 97 (61.8%) 0.6761
Angiotensin Receptor blocker 6 (8.8%) 6 (3.8%) 0.1252
Beta-blocker 34 (50.0%) 92 (58.6%) 0.2328
Hydralazine 2 (2.9%) 3 (1.9%) 0.6302
Nitrates 20 (29.4%) 28 (17.8%) 0.0517
Digoxin 11 (16.2%) 34 (21.7%) 0.3454
Calcium channel blocker 9 (13.2%) 24 (15.3%) 0.6896
SBP, systolic blood pressure; NYHA, New York Heart Association; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; ACE, angiotensin-converting
enzyme; BUN, blood urea nitrogen; sMDRD, simplified modification of diet in renal disease.
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Table 3 Univariable and multivariable predictors of worsening renal function in patients with acute heart failure. Odds ratios are presented as per standard
deviation increase, unless indicated otherwise
Univariable models Multivariable model Multivariable model
further adjusted for
weight change
Multivariable model
further adjusted for
relaxin treatment
Multivariable model
further adjusted for IV
diuretic dose
OR and 95% CI P-value OR and 95% CI P-value OR and 95% CI P-value OR and 95% CI P-value OR and 95% CI P-value
Peak drop in SBP within 48 h (per 13.8 mmHg increase) 1.59 (1.19–2.13) 0.002 1.45 (1.04–2.00) 0.0267 1.40 (1.00–1.96) 0.0492 1.45 (1.04–2.01) 0.0282 1.41 (1.01–1.98) 0.0454
Age (per 10.4 year increase) 1.62 (1.17–2.25) 0.004 1.58 (1.06–2.30) 0.0225 1.58 (1.07–2.34) 0.0215 1.63 (1.10–2.43) 0.0156 1.49 (1.00–2.22) 0.0498
Baseline creatinine (per 0.48 mg/dL increase) 1.22 (0.93–1.61) 0.16 1.41 (1.04–1.93) 0.0297 1.31 (0.95–1.81) 0.1036 1.40 (1.02–1.91) 0.036 1.30 (0.94–1.80) 0.1063
NYHA (i.v. vs. others) 1.93 (1.01–3.70) 0.046 1.80 (0.91–3.54) 0.0917 1.98 (0.99–3.98) 0.0549 1.84 (0.93–3.66) 0.08 1.77 (0.88–3.55) 0.1083
Admission BNP. 500 or NT-proBNP. 2000 pg/mL 1.70 (0.85–3.41) 0.14
Baseline SBP (per 17.9 mmHg increase) 1.43 (1.07–1.90) 0.015
Weight change (baseline to 48 h) (per 2.15 kg increase) 1.37 (1.00–1.86) 0.0487 1.43 (1.01–2.02) 0.0421
Relaxin (pooled treatment vs. placebo) 0.66 (0.32–1.38) 0.2728
Total dose i.v. loop diuretics Days 0–1 (per 132 mg increase) 1.92 (1.30–2.86) 0.0012 1.74 (1.15–2.62) 0.0084
NYHA, New York Heart Association; BNP, brain natriuretic peptide; NT-proBNP, N terminal pro brain natriuretic peptide.
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weight change during hospitalization was added to the model, then
less weight loss was related to an increased risk of worsening renal
function, although a drop in SBP remained independently related to
WRF as well (Table 3). The addition of the use of relaxin did not
change the model, and was not related to worsening renal function
(Table 3). Finally, a higher dose of loop diuretics was also indepen-
dently related to an increased risk of worsening renal function,
although a drop in SBP remained independently related to WRF
as well (Table 3). Figure 2 shows that in both patients with a
higher and a lower baseline SBP, a greater drop in SBP within
48 h was associated with a higher rate of WRF. Figure 3 shows
the continuous association between the maximum change in
blood pressure during the first 48 h and the risk of developing
WRF. Figure 4 shows the continuous association between baseline
SBP and the risk of developing WRF.
Relaxin treatment, worsening renal
function, and changes in blood pressure
The main results of the study have been published previously14,15
showing beneficial effects of relaxin on dyspnoea relief and clinical
outcomes. In Pre-RELAX-AHF, the SBP decrease from baseline to
24 h in relaxin-treated patients was larger than in placebo-treated
patients (mean decrease from baseline to 24 h was 14.0+
13.5 mmHg in placebo vs. 19.0+15.4 mmHg in all relaxin-treated
groups combined P ¼ 0.026). Most of this effect was driven by a
numerically larger drop in SBP in patients with higher baseline
SBP. In patients with SBP. median (140 mmHg) the drop in SBP
from baseline to 24 h was 15.0+17.1 mmHg in placebo vs.
23.3+17.4 mmHg in all relaxin-treated patients (P ¼ 0.037)
while in patients with SBP ≤ median at baseline the SBP drop to
24 h was 13.1+10.0 mmHg in placebo vs. 15.5+ 12.6 mmHg in
relaxin. Furthermore, after adjustment for baseline SBP, estimated
glomerular filteration rate (eGFR), and haemoglobin, the mean
peak SBP decrease within 48 h was greater in all relaxin-treated
patients compared with placebo-treated patients (234.5 and
230.1 mmHg in the relaxin- and placebo-treated patients,
respectively, pooled SD ¼ 12.2, P ¼ 0.025).
With regard to creatinine changes, neither lower (10 and 30 mg/
kg/day combined) nor higher (100 and 250 mg/kg/day combined)
relaxin doses were related to higher proportions of patients with
WRF than placebo (35.0, 30.9, and 26.3%, respectively; P ¼ 0.26
and 0.61 compared with placebo, respectively).
Discussion
The present study shows that a greater drop in SBP within the first
48 h after hospitalization for AHF was independently associated
with a higher risk of WRF. Worsening renal function was associ-
ated with a higher 60- and 180-day mortality. This is the first
Figure 2 Percentage of patients with worsening renal function
according to baseline systolic blood pressure (below or above
140 mmHg) and peak drop in systolic blood pressure (below
or above 32 mmHg) during the first 48 h.
Figure 3 Risk of worsening renal function plotted against a
peak drop in systolic blood pressure between baseline and
48 h. Data are presented as the mean (solid line) +95% confi-
dence limits (dashed and dotted lines).
Figure 4 Risk of worsening renal function plotted against base-
line systolic blood pressure during admission for acute heart
failure. Data are presented as the mean (solid line) +95% confi-
dence limits (dashed and dotted lines).
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study that reports on the association between an early change in
SBP and WRF in AHF patients.
Besides a larger early drop in SBP, higher age and poorer base-
line renal function were also independently related to an increased
risk of WRF. The association between poorer admission renal
function and the risk of WRF has been shown in a number of
previously published reports.3–12,17–19 In a univariable analysis,
we found that a higher baseline SBP also predicted WRF. This is
similar to four other studies. Owan et al.11 and Logeart et al.12
reported a higher risk of WRF during hospital admission for
AHF in patients with a history of hypertension. Krumholz et al.4
found that both a history of hypertension and an admission
blood pressure of .200 mmHg were associated with an increased
risk of WRF during a hospitalization for AHF. Similarly, Forman
et al.5 found that an admission SBP .160 mmHg was indepen-
dently associated with a higher risk of WRF. However, in the
present study, we additionally assessed changes in SBP after treat-
ment, and patients with a higher baseline SBP also had a larger
early drop in SBP. In a multivariable analysis, only a drop in SBP
remained independently related to a higher risk of WRF. This
suggests that the associations between baseline SBP and WRF
might be caused by the increased risk of a larger drop in SBP in
patients with a higher baseline SBP.
The pathophysiology behind our findings can be explained by
the auto-regulatory response of the kidney.20 When renal per-
fusion pressure rises due to an increased blood pressure, the
kidney will constrict its afferent arteriole, and possibly also its
interlobal arteries. When blood pressure drops, afferent vasodila-
tion occurs, and if blood pressure drops even further, efferent
vasoconstriction will occur as well. By doing so, the kidney can
maintain constant glomerular capillary perfusion, pressure, and fil-
tration, over a wide range of blood pressures. However, in case of
longstanding hypertension, there is a blunted ability of the
pre-glomerular circulation to dilate in response to a drop in SBP,
which will cause an exaggerated decrease in intraglomerular
pressure.13 This explanation is consistent with the findings of the
present study that both a higher baseline blood pressure at
baseline and a drop in blood pressure are related to a higher
risk of WRF.
Interestingly, less weight loss was also independently related to
an increased risk of worsening renal function. Patients with more
weight loss were probably more congested, which is associated
with higher central venous pressures. It is well known that a
higher central venous pressure has been closely related to an
impaired renal function in heart failure patients.21 So, in congested
patients, it is reasonable to assume that more decongestion is ben-
eficial for the kidney. A higher dose of diuretics was also related to
a higher risk of worsening renal function. This is not unexpected
since diuretics have been shown to impair renal function in heart
failure patients, probably by a so-called tubuloglomerular feedback
mechanism. Salt loss is sensed in the distal tubule of the kidney,
leading to release of adenosine. Adenosine then binds to the ade-
nosine A1-receptor, causing afferent vasoconstriction, thereby
reducing renal blood flow, which is a main determinant of renal
function in patient with HF.21 However, a recent randomized clini-
cal trial failed to show a beneficial effect of adenosine A1-blockers
in AHF.22
The prognostic importance of impaired renal function was
demonstrated by longer length of stay and increased 60- and
180-day mortality. This finding supports previous studies consist-
ently demonstrating that WRF is associated with increased mor-
tality.2–7 The rate of re-admission was not increased in patients
with WRF, which may potentially be related to their increased
mortality, reducing the number of patients with severe heart
failure that could have been re-admitted.
Relaxin has multiple actions potentially beneficial for the treat-
ment of patients with AHF, including increased production of
nitric oxide, vascular endothelial growth factor, and matrix metal-
loproteinases and inhibition of endothelin and angiotensin II.23 In
the Pre-RELAX-AHF study, relaxin was associated with a more
rapid and sustained relief of dyspnoea and other clinical outcomes,
with a favourable safety profile.14,15 Although patients treated with
relaxin had a larger drop in SBP throughout therapy, the additional
SBP reduction was, on average only 5 mmHg. This may be
related to several factors. First, patients treated with relaxin
tended to receive less i.v. nitrates and less i.v. loop diuretics.
This reduced concomitant therapy—which is probably the result
of treatment modifications by physicians observing higher blood
pressure (BP) drops in patients treated with relaxin—may
explain some of the reduced BP decrease observed with relaxin.
Second, the BP lowering effect of relaxin was dependent on base-
line BP and was more pronounced (and significant) in patients with
higher (.median) baseline SBP than in patients with lower
(≤median) systolic BP. This effect is different to results observed
in case of other therapies with vasodilating properties, suggesting
that the effects of relaxin are more in line with countering vaso-
constriction than simple vasodilatation, a property that may
explain some of its efficacy in Pre-RELAX-AHF. Overall, there
was a neutral effect of relaxin on renal function, compared with
placebo. This is in contrast to the findings of favourable effects
of relaxin on intra-renal haemodynamics, and renal function in
experimental studies.23 In both male and ovariectomized female
rats, relaxin increased GFR, and effective renal plasma flow by 33
and 49% over baseline, respectively.24 These effects were mediated
by the endothelial endothelin B receptor subtype, presumably on
endothelial cells and nitric oxide. Irrespective of the mechanism,
data from the present study support the use of the lower dose
of 30 mg/kg/day of relaxin in an ongoing phase III trial. The
present data are clinically relevant, since patients with WRF are
at risk of a longer length of stay and higher 60- and 180-day mor-
tality. This study demonstrates that specific attention should be
paid to renal function in patients with a high SBP at admission
and a larger drop in SBP during the first 48 h. Although a causal
relationship between a change in blood pressure and WRF has
not been proven, it seems reasonable to suggest that a sudden
drop in blood pressure might be harmful for the kidneys.12 In
fact, renal blood flow seems to be the major driving factor that
explains the frequent occurrence of renal dysfunction in patients
with heart failure.20,21
There are a few important limitations to this study. First, this is a
post-hoc analysis of the Pre-RELAX-AHF study, which was not
specifically designed to study the effects of relaxin on renal func-
tion. Second, the number of patients was small, and these results
should therefore be considered as hypothesis generating. Third,
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the most important limitation is the previously discussed relation
between a higher baseline SBP and a larger drop in SBP.
However, from a clinical perspective, these will be largely the
same patients. Our data therefore suggest that careful monitoring
and lowering of blood pressure in these patients might prevent
WRF, and might even improve clinical outcome.
In conclusion, in patients hospitalized for AHF, WRF is indepen-
dently predicted by a greater drop in SBP during the first 48 h of
hospitalization. Worsening renal function was strongly related to
a poorer clinical outcome up to 180 days after hospital admission.
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